Lysosomal storage disorders - Fabry disease and Gaucher disease

被引:0
|
作者
Schmitz, Lucia Segura [1 ]
Hennermann, Julia B. [2 ]
Lollert, Andre [3 ]
机构
[1] Unimed Mainz, Klin & Poliklin Kinder & Jugendmed, Villa Metab, Langenbeckstr 1, D-55131 Mainz, Germany
[2] Univ Med Mainz, Klin & Poliklin Kinder & Jugendmed, Sekt Padiat Stoffwechselerkrankungen, Villa Metab, Mainz, Germany
[3] Univ Med Mainz, Klin & Poliklin Diagnost & Intervent Radiol, Sekt Kinderradiol, Mainz, Germany
关键词
storage disorders; Fabry disease; Gaucher disease; enzyme replacement therapy;
D O I
10.1055/a-2295-1592
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lysosomal storage disorders (LSD) are a heterogenous group of inborn errors of metabolism due to lysosomal malfunction. LSDs affect 1 in 5000 live births, albeit every LSD itself has a low incidence. The most common LSDs are Fabry disease and Gaucher disease. The underlying cause mainly is an enzyme deficiency but may also be due to defects in transport or activation proteins, which result in progressive intra- and extra-lysosomal accumulation of undegraded storage material. The lysosomes play a key role in degradation and cellular recycling of macromolecules. Besides disturbance of cellular function, substrate accumulation may result in secondary toxic and/or inflammatory processes. For treatment of Fabry and Gaucher disease, several therapeutic approaches are approved including enzyme replacement therapy, chaperon therapy for Fabry disease and substrate reduction therapy for Gaucher disease.
引用
收藏
页码:1263 / 1269
页数:7
相关论文
共 50 条
  • [1] Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease
    Crivaro, Andrea N.
    Mucci, Juan M.
    Bonder, Constanza M.
    Ormazabal, Maximiliano E.
    Ceci, Romina
    Simonaro, Calogera
    Rozenfeld, Paula A.
    PLOS ONE, 2019, 14 (05):
  • [2] Biomarkers in Lysosomal Storage Disorders With Reference to Gaucher Disease
    Cox, Timothy M.
    CLINICAL THERAPEUTICS, 2009, 31 : S183 - S184
  • [3] Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease
    Aerts, Johannes M. F. G.
    Kuo, Chi-Lin
    Lelieveld, Lindsey T.
    Boer, Daphne E. C.
    van der Lienden, Martijn J. C.
    Overkleeft, Herman S.
    Artola, Marta
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2019, 53 : 204 - 215
  • [4] PATHOGENESIS OF LYSOSOMAL STORAGE DISORDERS AS ILLUSTRATED BY GAUCHER DISEASE
    AERTS, JMFG
    VANWEELY, S
    BOOT, R
    HOLLAK, CEM
    TAGER, JM
    JOURNAL OF INHERITED METABOLIC DISEASE, 1993, 16 (02) : 288 - 291
  • [5] Lysosomal Storage Disorders and Parkinson's Disease: Gaucher Disease and Beyond
    Shachar, Tamar
    Lo Bianco, Christophe
    Recchia, Alessandra
    Wiessner, Christoph
    Raas-Rothschild, Annick
    Futerman, Anthony H.
    MOVEMENT DISORDERS, 2011, 26 (09) : 1593 - 1604
  • [6] Anderson-Fabry Disease and Other Lysosomal Storage Disorders
    Nagueh, Sherif F.
    CIRCULATION, 2014, 130 (13) : 1081 - 1090
  • [7] Fabry Disease (A Kind of Lysosomal Storage Disease)
    Karimzadeh, Parvaneh
    IRANIAN JOURNAL OF CHILD NEUROLOGY, 2012, 6 (04) : 6 - 6
  • [8] Therapeutic strategies to ameliorate lysosomal storage disorders - a focus on Gaucher disease
    Sawkar, A. R.
    D'Haeze, W.
    Kelly, J. W.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (10) : 1179 - 1192
  • [9] Therapeutic strategies to ameliorate lysosomal storage disorders – a focus on Gaucher disease
    A. R. Sawkar
    W. D’Haeze
    J. W. Kelly
    Cellular and Molecular Life Sciences CMLS, 2006, 63 : 1179 - 1192
  • [10] The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease
    Hollak, Carla E. M.
    Weinreb, Neal J.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 29 (02) : 205 - 218